Dirk Trauner

8178496, May 15, 2012

Dec 18, 2008

12/338880

Dirk Trauner - San Francisco CA, US
Ehud Y. Isacoff - Berkeley CA, US
Matthew Volgraf - Oakland CA, US
Pablo Ignacio Gorostiza Langa - Barcelona, ES

The Regents of the University of California - Oakland CA

C07C 323/12
A61A 38/00

514 173, 514 174, 435 78, 435334, 4352921

The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

20070128662, Jun 7, 2007

Nov 17, 2006

11/601591

Ehud Isacoff - Berkeley CA, US
Richard Kramer - Oakland CA, US
Dirk Trauner - San Francisco CA, US
Matthew Banghart - Oakland CA, US
Matthew Volgraf - Oakland CA, US
Pablo Langa - Barcelona, ES

G01N 33/53
C07K 14/195
C07H 21/04
C12P 21/06
C12N 15/74
C12N 1/21
A61K 38/16

435007100, 435069100, 435252300, 435471000, 530350000, 536023500, 514012000

The present invention provides a synthetic regulator of protein function, which regulator is a light-sensitive regulator. The present invention further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present invention further provides methods of modulating protein function, involving use of light. The present invention further provides methods of identifying agents that modulate protein function.

20210322451, Oct 21, 2021

Aug 12, 2019

17/267721

- New York NY, US
Dirk TRAUNER - New York NY, US
Christopher James ARP - The Woodlands TX, US

A61K 31/7028
A61P 25/28

Provided are compositions and methods for memory enhancement, including recovery of memory impairment. The compositions and methods relate to mannose-6-phosphate and derivatives of mannose-6-phosphate. The methods relate to administration of M6P or derivatives thereof to individuals in whom memory enhancement is desired.

20210315914, Oct 14, 2021

Aug 12, 2019

17/267715

- New York NY, US
Dirk TRAUNER - New York NY, US
Christopher James ARP - The Woodlands TX, US

A61K 31/7024
A61K 38/30
A61P 25/00

Provided are methods for treatment of neurodevelopmental disorders, such as Angelman Syndrome and autism comprising administering to an individual a composition comprising an agonist ligand of IGF-2 receptor. The agonist ligand of IGF-2 receptor may be IGF-2, or mannose-6-phosphate or a derivative thereof. Compositions comprising mannose-6-phosphate derivatives are also disclosed.

20200308539, Oct 1, 2020

Sep 21, 2018

16/649525

- Oakland CA, US
Dirk Trauner - New York NY, US
Johannes Broichhagen - Heidelberg, DE
Joshua Levitz - New York NY, US

C12N 5/079
A61N 5/06
C07K 14/705
C07K 16/00
C12N 5/0793
C12N 5/077

The present disclosure provides a conjugate comprising: a) an affinity agent that specifically binds a target ligand-binding polypeptide; and b) a photoisomerizable regulator comprising: i) a photoisomerizable moiety; and ii) a ligand that binds to the target ligand-binding polypeptide. The present disclosure provides cells comprising a conjugate of the present disclosure. The present disclosure provides methods of using a conjugate of the present disclosure to modulate activity of a target polypeptide, and to modulate activity of a target cell or cell population.